Eli Lilly’s LLY0.57%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

Most of the focus on the new rankings this week was on No. 1 exchanging hands on the men’s side, with Jannik Sinner taking the top spot back from Carlos Alcaraz after Monte Carlo. But further down the ...

The Food and Drug Administration is asking Eli Lilly to gather more safety data on its new weight loss pill, Foundayo, including whether it could be linked to liver and heart problems, according to ...

Eli Lilly (LLY) reported Q4 revenue of $19.29B up 42.6% YoY, with Mounjaro generating $7.41B (up 110%) and Zepbound adding $4.26B (up 123%). Novo Nordisk (NVO) posted Q4 revenue down 7.6% YoY and cut ...

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy pretty vague. This time, Lilly has returned to antibody-drug conjugates (ADCs), ...

The U.S. Food and Drug Administration has asked Eli Lilly for more data on liver injury linked to its newly approved obesity pill, according to a letter posted on the health regulator's website. The ...

Following a quiet stretch, the legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva gaining favor on appeal after a 2023 reversal of its prior patent win. The ...

April 16 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday its newly approved obesity pill was not inferior to a widely used ‌long-acting insulin at lowering the risk of major heart ...

April 14 (Reuters) - The U.S. Food and Drug Administration has asked Eli Lilly (LLY.N), opens new tab for more data on liver injury linked to its newly approved obesity pill, according to a letter ...

Eli Lilly has rolled out Foundayo, its oral GLP-1 pill, directly to consumers through its LillyDirect cash-pay channel, as well as to telehealth providers and pharmacies across the U.S. The drug is a ...

Eli Lilly has a stronger weight-loss portfolio than Novo Nordisk. Eli Lilly also has a deep pipeline beyond its core therapeutic area. Novo Nordisk's shares could be a bargain at current levels. Novo ...

"The best scripts that I've ever read are all independent or have never been made, which is sad," says the star of the Mubi comedy-drama 'Hal & Harper.' By Brande Victorian Deputy Awards Editor The ...